2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trialIan Smith, Martine Piccart, Marion Procter et al.|The Lancet|2007Cited by 1.5k
Mechanisms of tamoxifen resistanceAlistair Ring, Mitch Dowsett|Endocrine Related Cancer|2004Cited by 652
Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination TrialMitch Dowsett, Aman U. Buzdar, Craig Allred et al.|Journal of Clinical Oncology|2008Cited by 464
Assessment of Molecular Relapse Detection in Early-Stage Breast CancerIsaac García-Murillas, Nicholas C. Turner, Neha Chopra et al.|JAMA Oncology|2019Cited by 425
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)Matthew J. Ellis, Kelly K. Hunt, Vera J. Suman et al.|Journal of Clinical Oncology|2017Cited by 411